Resultats globals: 6 registres trobats en 0.02 segons.
Articles, 6 registres trobats
Articles 6 registres trobats  
1.
11 p, 265.1 KB Safinamide in clinical practice : A Spanish multicenter cohort study / Martí-Andrés, Gloria (Clínica Universidad de Navarra) ; Jiménez-Bolaños, Rayco (Hospital Universitario Insular de Gran Canaria) ; Arbelo-González, José Matias (Hospital Universitario Insular de Gran Canaria) ; Pagonabarraga Mora, Javier (Institut d'Investigació Biomèdica Sant Pau) ; Duran-Herrera, Carmen (Hospital Universitario de Badajoz) ; Valenti-Azcarate, Rafael (Clínica Universidad de Navarra) ; Luquin, Mª Rosario (Clínica Universidad de Navarra) ; Universitat Autònoma de Barcelona
Safinamide is an approved drug for the treatment of motor fluctuations of Parkinson's Disease (PD) patients with a potential benefit on non-motor symptoms (NMS). A retrospective multicenter cohort study was conducted, in which the clinical effect of safinamide on both motor and NMS was assessed by the Clinical Global Impression of Change scale. [...]
2019 - 10.3390/brainsci9100272
Brain sciences, Vol. 9 Núm. 10 (october 2019) , p. 272  
2.
20 p, 1.0 MB Feline Injection-Site Sarcoma and Other Adverse Reactions to Vaccination in Cats / Hartmann, Katrin (Centre for Clinical Veterinary Medicine) ; Egberink, Herman (University of Utrecht. Department of Biomolecular Health Sciences) ; Möstl, Karin (University of Veterinary Medicine. Department for Pathobiology) ; Addie, Diane D (Maison Zabal) ; Belák, Sándor (Swedish University of Agricultural Sciences. Department of Biomedical Sciences and Veterinary Public Health (BVF)) ; Boucraut-Baralon, Corine (Scanelis Veterinary Test Laboratory) ; Frymus, Tadeusz (Warsaw University of Life Sciences-SGGW. Department of Small Animal Diseases with Clinic) ; Lloret, Albert (Universitat Autònoma de Barcelona. Hospital Clínic Veterinari) ; Hofmann-Lehmann, Regina (University of Zuich. Department of Clinical Diagnostics and Services) ; Marsilio, Fulvio (Università degli Studi di Teramo. Faculty of Veterinary Medicine) ; Pennisi, Maria Grazia (Università di Messina. Dipartimento di Scienze Veterinarie) ; Tasker, Séverine (Linnaeus Veterinary) ; Thiry, Etienne (Liège University. Department of Infectious and Parasitic Diseases) ; Truyen, Uwe (University of Leipzig. Institute of Animal Hygiene and Veterinary Public Health) ; Hosie, Margaret J (University of Glasgow Centre for Virus Research)
Vaccine-associated adverse events (VAAEs), including feline injection-site sarcomas (FISSs), occur only rarely but can be severe. Understanding potential VAAEs is an important part of informed owner consent for vaccination. [...]
2023 - 10.3390/v15081708
Viruses, Vol. 15 (august 2023)  
3.
10 p, 389.9 KB A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation / Nevens, Frederik (University Hospitals Leuven (Bèlgica)) ; Gustot, Thierry (C.U.B. Erasme Hospital) ; Laterre, Pierre-François (Cliniques Universitaires Saint-Luc) ; Lasser, Luc L. (CHU Brugmann) ; Haralampiev, Lyudmil E. (Multiprofile Hospital for Active Treatment (MEDICA), Ruse) ; Vargas, Victor (Hospital Universitari Vall d'Hebron) ; Lyubomirova, Desislava (University Multiprofile Hospital for Active Treatment "Georgi Stranski") ; Albillos, Agustín (Hospital Universitario Ramón y Cajal (Madrid)) ; Najimi, Mustapha (Institute of Experimental and Clinical Research, Brussels) ; Michel, Sébastien (Promethera Biosciences, Mont-Saint-Guibert) ; Stoykov, Ivaylo (Promethera Biosciences, Mont-Saint-Guibert) ; Gordillo, Noelia (Promethera Biosciences, Mont-Saint-Guibert) ; Vainilovich, Yelena (Promethera Biosciences, Mont-Saint-Guibert) ; Barthel, Virginie (Promethera Biosciences, Mont-Saint-Guibert) ; Clerget-Chossat, Nathalie (Promethera Biosciences, Mont-Saint-Guibert) ; Sokal, Etienne M. (Cliniques Universitaires Saint-Luc, UCLouvain, Pediatric Hepatology & Gastroenterology Unit) ; Universitat Autònoma de Barcelona
Human allogeneic liver-derived progenitor cells (HALPC, HepaStem®; Promethera Biosciences, Mont-Saint-Guibert, Belgium) are an advanced therapy medicinal product that could potentially alleviate systemic inflammation and ameliorate liver function in patients with acute-on-chronic liver failure (ACLF) or acute decompensation of cirrhosis (AD). [...]
2021 - 10.1016/j.jhepr.2021.100291
JHEP Reports, Vol. 3 (april 2021)  
4.
13 p, 267.6 KB Issues Impacting Adverse Event Frequency and Severity : Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan / Kudrow, David (California Medical Clinic for Headache) ; Krege, John H. (Eli Lilly and Company, Indianapolis) ; Hundemer, Hans P. (Eli Lilly and Company, Bad Homburg) ; Berg, Paul H. (Eli Lilly and Company, Indianapolis) ; Khanna, Rashna (Eli Lilly and Company, Erl Wood) ; Ossipov, Michael H. (Syneos Health, Clinical Division) ; Pozo-Rosich, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
We explore factors that may have contributed to differences in treatment-emergent adverse events in the phase 2 and phase 3 lasmiditan clinical trials. Phase 2 and phase 3 trials showed that the centrally penetrant 5-HT agonist, lasmiditan, was effective; higher frequency and severity of adverse events (AEs) were seen in phase 2. [...]
2020 - 10.1111/head.13731
Headache, Vol. 60 (january 2020) , p. 576-588  
5.
8 p, 500.8 KB Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer / Gueorguieva, Ivelina (Eli Lilly and Company (United Kingdom)) ; Cleverly, Ann (Eli Lilly and Company (United Kingdom)) ; Desaiah, Durisala (Eli Lilly and Company (USA)) ; Azaro, Analía (Hospital Universitari Vall d'Hebron) ; Seoane Suárez, Joan (Vall d'Hebron Institut d'Oncologia) ; Braña, Irene (Hospital Universitari Vall d'Hebron) ; Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ; Miles, Colin (Eli Lilly and Company (United Kingdom)) ; Lahn, Michael M.. (Eli Lilly and Company (USA)) ; Mitchell, Malcolm I (Eli Lilly and Company (USA)) ; Rodón Ahnert, Jordi (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunisertib formulations developed using the roller compaction (RC) dry-milled (RCD) and RC slurry-milled (RCS) processes, compared with the existing formulation developed using the high-sheer wet granulation (HSWG) process. [...]
2016 - 10.7573/dic.212303
Drugs in Context, Vol. 5 (December 2016) , art. 201303  
6.
14 p, 606.8 KB Cafeína: un nutriente, un fármaco, o una droga de abuso / Pardo Lozano, Ricardo (Institut Hospital del Mar d'Investigacions Mèdiques) ; Álvarez García, Yolanda ; Barral Tafalla, Diego ; Farre, Magi (Institut Hospital del Mar d'Investigacions Mèdiques)
El café, el té, el chocolate y los refrescos de cola son las principales fuentes de cafeína, que es consumida en casi todas las edades y estratos socioeconómicos. La cafeína es un antagonista competitivo de los receptores adenosínicos del SNC. [...]
Coffee, tea, chocolate and caffeinated drinks are the main sources of caffeine, which is consumed in almost all ages and socioeconomic levels. Caffeine acts as a non-selective adenosine receptor antagonist in the central nervous system. [...]

2007
Adicciones, Vol. 19, Núm. 3 (2007) , p. 225-238  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.